HIGHLIGHTS
- who: Cheng Huang from the Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Fenglin Road, Shanghai, China have published the research work: Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis, in the Journal: (JOURNAL)
- what: The authors report a retrospective analysis of the response of HCC lesions in different organs (organ-specific response rate ) to first-line treatment with combined lenvatinib and anti-PD-1 antibodies. The authors evaluate treatment response in macrovascular tumor thrombi (MVTT . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.